These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

578 related articles for article (PubMed ID: 27067119)

  • 1. Therapeutic application of anti-angiogenic nanomaterials in cancers.
    Mukherjee S; Patra CR
    Nanoscale; 2016 Jul; 8(25):12444-70. PubMed ID: 27067119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging applications of anti-angiogenic nanomaterials in oncotherapy.
    Tang B; Ma W; Lin Y
    J Control Release; 2023 Dec; 364():61-78. PubMed ID: 37871753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel endogenous angiogenesis inhibitors and their therapeutic potential.
    Rao N; Lee YF; Ge R
    Acta Pharmacol Sin; 2015 Oct; 36(10):1177-90. PubMed ID: 26364800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent Advancements of Nanomedicine towards Antiangiogenic Therapy in Cancer.
    Mukherjee A; Madamsetty VS; Paul MK; Mukherjee S
    Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31936832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effective treatment of intractable diseases using nanoparticles to interfere with vascular supply and angiogenic process.
    Hoseinzadeh A; Ghoddusi Johari H; Anbardar MH; Tayebi L; Vafa E; Abbasi M; Vaez A; Golchin A; Amani AM; Jangjou A
    Eur J Med Res; 2022 Nov; 27(1):232. PubMed ID: 36333816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiogenic factors as potential drug target: efficacy and limitations of anti-angiogenic therapy.
    Gacche RN; Meshram RJ
    Biochim Biophys Acta; 2014 Aug; 1846(1):161-79. PubMed ID: 24836679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Broad targeting of angiogenesis for cancer prevention and therapy.
    Wang Z; Dabrosin C; Yin X; Fuster MM; Arreola A; Rathmell WK; Generali D; Nagaraju GP; El-Rayes B; Ribatti D; Chen YC; Honoki K; Fujii H; Georgakilas AG; Nowsheen S; Amedei A; Niccolai E; Amin A; Ashraf SS; Helferich B; Yang X; Guha G; Bhakta D; Ciriolo MR; Aquilano K; Chen S; Halicka D; Mohammed SI; Azmi AS; Bilsland A; Keith WN; Jensen LD
    Semin Cancer Biol; 2015 Dec; 35 Suppl(Suppl):S224-S243. PubMed ID: 25600295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Engineered Nanoparticles for Effective Redox Signaling During Angiogenic and Antiangiogenic Therapy.
    Nethi SK; Barui AK; Mukherjee S; Patra CR
    Antioxid Redox Signal; 2019 Feb; 30(5):786-809. PubMed ID: 29943661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current Challenges of Cancer Anti-angiogenic Therapy and the Promise of Nanotherapeutics.
    Abdalla AME; Xiao L; Ullah MW; Yu M; Ouyang C; Yang G
    Theranostics; 2018; 8(2):533-548. PubMed ID: 29290825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current status and future of anti-angiogenic drugs in lung cancer.
    Yan X; Zhao Z; Tang H
    Clin Exp Med; 2023 Oct; 23(6):2009-2023. PubMed ID: 36920592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.
    Gacche RN; Meshram RJ
    Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Angiogenesis - possibilities, problems and perspectives].
    Kurzyk A
    Postepy Biochem; 2015; 61(1):25-34. PubMed ID: 26281351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential Role of Natural Compounds as Anti-Angiogenic Agents in Cancer.
    Shanmugam MK; Warrier S; Kumar AP; Sethi G; Arfuso F
    Curr Vasc Pharmacol; 2017; 15(6):503-519. PubMed ID: 28707601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and development of polymer conjugates as anti-angiogenic agents.
    Segal E; Satchi-Fainaro R
    Adv Drug Deliv Rev; 2009 Nov; 61(13):1159-76. PubMed ID: 19699248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mitochondria as targets in angiogenesis inhibition.
    Park D; Dilda PJ
    Mol Aspects Med; 2010 Feb; 31(1):113-31. PubMed ID: 19995570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant human endostatin as a potential anti-angiogenic agent: therapeutic perspective and current status.
    Anakha J; Dobariya P; Sharma SS; Pande AH
    Med Oncol; 2023 Dec; 41(1):24. PubMed ID: 38123873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular regulation of tumor angiogenesis: mechanisms and therapeutic implications.
    Harper J; Moses MA
    EXS; 2006; (96):223-68. PubMed ID: 16383021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Novel angiogenesis inhibitors for molecular target therapy of cancer].
    Osada H; Kakeya H
    Nihon Rinsho; 2004 Jul; 62(7):1257-63. PubMed ID: 15283141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiogenic signaling pathways and anti-angiogenic therapy for cancer.
    Liu ZL; Chen HH; Zheng LL; Sun LP; Shi L
    Signal Transduct Target Ther; 2023 May; 8(1):198. PubMed ID: 37169756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-angiogenic alternatives to VEGF blockade.
    Khan KA; Bicknell R
    Clin Exp Metastasis; 2016 Feb; 33(2):197-210. PubMed ID: 26620208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.